Klaria Pharma, RTHS to Develop Quicker Migraine Detection, Treatment

12:59 AM EDT, 09/08/2026 (MT Newswires) -- Klaria Pharma (KLAR.ST) signed a partnership agreement with Swedish medical technology company RTHS to develop earlier detection of migraine before symptoms appear. RTHS' technology, together with algorithms, measures subtle changes in an individual's blood flow dynamics to detect blood flow changes indicative of an impending migraine attack, according to a Monday release. Coupled with the Stockholm-listed pharmaceutical company's Sumatriptan Alginate Film medication, the collaboration will facilitate faster detection and intervention for migraine patients.